Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ASND 
Ascendis Pharma AS (ASND)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/03/2025: ASND (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
16 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $231.2
Year Target Price $231.2
| 12 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.15% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/03/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.42B USD | Price to earnings Ratio - | 1Y Target Price 231.2 |
Price to earnings Ratio - | 1Y Target Price 231.2 | ||
Volume (30-day avg) 16 | Beta 0.36 | 52 Weeks Range 111.09 - 183.00 | Updated Date 06/30/2025 |
52 Weeks Range 111.09 - 183.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.79 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -92.67% | Operating Margin (TTM) -103.23% |
Management Effectiveness
Return on Assets (TTM) -22.39% | Return on Equity (TTM) -818.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10790064343 | Price to Sales(TTM) 28.26 |
Enterprise Value 10790064343 | Price to Sales(TTM) 28.26 | ||
Enterprise Value to Revenue 25.03 | Enterprise Value to EBITDA -20.75 | Shares Outstanding 60494200 | Shares Floating 59902597 |
Shares Outstanding 60494200 | Shares Floating 59902597 | ||
Percent Insiders 0.78 | Percent Institutions 113.57 |
Analyst Ratings
Rating 4 | Target Price 231.2 | Buy 4 | Strong Buy 12 |
Buy 4 | Strong Buy 12 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ascendis Pharma AS
Company Overview
History and Background
Ascendis Pharma AS was founded in 2006. It is a biopharmaceutical company focused on developing therapies to address unmet medical needs, primarily in endocrinology and oncology. The company leverages its TransCon technology platform to create sustained-release therapies.
Core Business Areas
- Endocrinology: Focuses on developing therapies for growth disorders, rare endocrine diseases, and other endocrine-related conditions, with its lead product being Skytrofa (lonapegsomatropin-tcgd) for pediatric growth hormone deficiency (GHD).
- Oncology: Developing TransCon prodrugs designed to unleash cancer-fighting agents directly into tumors while sparing normal tissues. They are still in Phase 1 testing.
- Rare Disease: Addresses the unmet needs of rare disease patients, researching and developing therapies for different indications.
Leadership and Structure
Jan Mikkelsen is the President and CEO. The company has a board of directors and operates with a functional organizational structure focusing on research and development, commercialization, and business development.
Top Products and Market Share
Key Offerings
- Skytrofa (lonapegsomatropin-tcgd): A long-acting growth hormone approved for pediatric growth hormone deficiency (GHD). Expected peak sales are estimated at $1 billion per year. Competitors include Pfizer's Genotropin, Novo Nordisk's Norditropin, and Eli Lilly's Humatrope, although Skytrofa offers once-weekly dosing, giving it a competitive advantage.
- TransCon CNP (C-type Natriuretic Peptide): A product candidate in phase 2 for achondroplasia, a form of dwarfism. Competitors are BioMarin's Voxzogo. Revenue is still pending.
- TransCon hGH: A next generation human growth hormone prodrug. A phase 1 candidate for hypoparathyroidism. Competitors are Takeda Pharmaceuticals's Natpara and Ascendis' own Skytrofa.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated, with significant investment in research and development. The market for growth hormone therapies is well-established and growing. Orphan drugs receive market exclusivity, incentivizing the development of treatments for rare diseases. The oncology market is highly competitive.
Positioning
Ascendis Pharma AS is positioned as an innovative biopharmaceutical company leveraging its TransCon technology to develop differentiated therapies with improved pharmacological profiles. They aim to address unmet medical needs in endocrinology and oncology with superior therapies for orphan disease.
Total Addressable Market (TAM)
The total addressable market for growth hormone deficiency is estimated to be several billion dollars globally. Ascendis Pharma AS, with Skytrofa, is positioned to capture a significant portion of this TAM due to its once-weekly dosing convenience. Achondroplasia has an estimated total market value of $1B. Oncology therapeutics are much larger with multiple players.
Upturn SWOT Analysis
Strengths
- Proprietary TransCon technology
- Approved product (Skytrofa) generating revenue
- Strong pipeline of product candidates
- Experienced management team
- Once-weekly GHD therapy
Weaknesses
- Reliance on a single product for revenue
- High R&D expenses
- Competition from established pharmaceutical companies
- Dependent on regulatory approvals
- Currently loss-making
Opportunities
- Expanding indications for Skytrofa
- Advancing pipeline candidates through clinical development
- Partnerships and collaborations
- Geographic expansion
- Addressing other indications with TransCon technology
Threats
- Clinical trial failures
- Regulatory hurdles
- Patent expirations
- Competition from biosimilars
- Adverse safety events
Competitors and Market Share
Key Competitors
- PFE
- NVO
- LLY
- BMRA
Competitive Landscape
Ascendis Pharma AS has a competitive advantage with Skytrofa's once-weekly dosing. However, they face competition from established pharmaceutical companies with broader product portfolios and greater resources. Ascendis Pharma AS faces a growing competitive landscape.
Growth Trajectory and Initiatives
Historical Growth: Ascendis Pharma AS has experienced rapid growth in recent years driven by the approval and launch of Skytrofa.
Future Projections: Analysts expect revenue growth to continue as Skytrofa gains market share and pipeline candidates advance. Profitability is expected in the coming years as revenue scales.
Recent Initiatives: Expanding Skytrofa commercialization efforts, advancing TransCon CNP in achondroplasia, and developing new TransCon candidates for oncology.
Summary
Ascendis Pharma AS is a growing biopharmaceutical company with a novel technology platform and an approved product, Skytrofa, driving revenue growth. The company faces challenges including ongoing losses, high R&D expenses, and competition. Successful pipeline development and commercialization are critical for long-term success. The future depends heavily on clinical trial results and market penetration.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Company website
- ClinicalTrials.gov
- Company 10K reports
- Market research reports.
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share figures are estimates and may vary. Financial data is based on the most recent available information and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ascendis Pharma AS
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-01-28 | President, CEO, Member of Executive Board & Executive Director Mr. Jan Moller Mikkelsen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1017 | Website https://ascendispharma.com |
Full time employees 1017 | Website https://ascendispharma.com | ||
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.